The overall incidence of depression and/or anxiety was lower in GLP1-RA users than non-users (6.80 versus 9.36 per 1,000 person-years), with an aHR of 0.8 (95% CI: 0.67–0.95) for users, after controlling for demographic factors, comorbidities and medications (Table 2). Here, GLP1R is linked to depressive symptom measurement.